HCV

Our Partnered HCV Compounds

Enanta has discovered novel protease inhibitors for use against the hepatitis C virus (HCV). These protease inhibitors, developed through Enanta’s collaboration with AbbVie, include paritaprevir, part of AbbVie’s currently marketed HCV regimens, and glecaprevir, Enanta’s second protease inhibitor product.

 

Paritaprevir, a Protease Inhibitor for HCV Infection

Paritaprevir is an NS3/4A protease inhibitor discovered during the ongoing collaboration between Enanta and AbbVie for HCV protease inhibitors and the first developed in AbbVie’s treatment regimens that include protease inhibitors.

Paritaprevir is one of the direct-acting-antivirals in VIEKIRA PAK and the other treatment regimens that AbbVie developed and has been marketing worldwide for HCV genotypes 1 and 4.

AbbVie is responsible for all worldwide commercialization of paritaprevir-containing treatment regimens for HCV.

HCV Programs

Glecaprevir, Enanta’s Second HCV Protease Inhibitor

Glecaprevir is the second protease inhibitor discovered within the Enanta-AbbVie collaboration.

Glecaprevir was designed to enable once-daily dosing without ritonavir or ribavirin. AbbVie has co-formulated it in a fixed-dose combination with AbbVie’s new NS5A inhibitor, pibrentasvir (ABT-530). The European Commission has granted AbbVie Marketing Authorization for MAVIRET™ (glecaprevir/pibrentasvir) in the E.U. , and the U.S. Food and Drug Administration has approved MAVYRET™ (glecaprevir/pibrentasvir).  Glecaprevir/pibrentasvir or G/P,  is currently under priority review by the Japanese Ministry of Health, Labour and Welfare.

Our HCV Opportunity

Enanta has used a successful partnership with AbbVie to compete in the highly competitive market for hepatitis C virus (HCV) treatments. Since 2006 we have worked with our partner AbbVie (the former research-based pharmaceutical business of Abbott Laboratories) to develop protease inhibitors to treat HCV infection. Enanta is eligible to receive annually tiered, per product royalties ranging from the low double digits up to twenty percent, or up to the high teens on a blended basis, based on the annual net sales of each product developed under the agreement. In addition, Enanta is eligible to earn up to a total of $80 million in commercialization regulatory approval milestones payments from AbbVie for G/P, a majority of which are anticipated in calendar 2017.

Our HCV Opportunity

Read about our other areas of research

For an overview of our research, including our licensed products, please see Our Pipeline.